Sarah Cannon

Latest from Sarah Cannon

RET Inhibitor Enters the Therapeutic Ring in Multiple Settings

October 14, 2020

Article

Todd Bauer, MD, discusses how the highly specific nature of selpercatinib leads to greater tolerability than multityrosine kinase inhibitors and its frontline potential.

Dr. Burris on the Exploration of PARP Inhibitors in TNBC

October 08, 2020

Video

Howard A. “Skip” Burris, III, MD, FASCO, FACP, discusses the exploration of PARP inhibitors in triple-negative breast cancer.

Dr. Hamilton on the Exploration of CDK4/6 Inhibitors in Breast Cancer

October 06, 2020

Video

Erika P. Hamilton, MD, discusses the exploration of CDK4/6 Inhibitors in HER2-positive breast cancer.

Dr. Hamilton on Initial Findings From the LIO-1 Trial in Advanced Metastatic Tumors

October 01, 2020

Video

Erika P. Hamilton, MD, highlights initial findings from the ongoing phase 1b/2 LIO-1 trial in advanced metastatic tumors.

Dr. Bachier on the Potential Benefits of Liso-Cel in DLBCL

September 17, 2020

Video

Carlos R. Bachier, MD, discusses the investigational CAR T-cell therapy lisocabtagene maraleucel in diffuse large B-cell lymphoma.

ASCO 2020 Data Point to New Wave of Immunotherapy Approaches in NSCLC

September 10, 2020

Article

David R. Spigel, MD, discusses the IMpower110, CYPRESS-1, and CANOPY-A trials, and spoke to the potential future outlook of drug development in NSCLC.